Welcome to our dedicated page for Else Nutrition H news (Ticker: BABYF), a resource for investors and traders seeking the latest updates and insights on Else Nutrition H stock.
Else Nutrition Holdings Inc. reports developments tied to its plant-based nutrition business for infants, toddlers, children, and adults. The company’s updates center on whole-food, non-soy, non-dairy products, including toddler nutrition and baby cereal lines made with ingredients such as almonds, buckwheat, and tapioca.
Recurring news themes include U.S. infant-formula regulatory activity, FDA guidance on protein standards, product pipeline positioning, sales milestones, operating and financial progress, shareholder meeting results, governance matters, and capital-structure actions related to convertible funding agreements and equity issuance approvals.
Else Nutrition (OTCQX:BABYF) reported Q1 2026 results, with revenue of $1.5 million versus $2.1 million a year ago, mainly due to out-of-stock issues.
Gross margin rose to 40% from 24%, quarterly net loss declined to about $0.6 million from $3.4 million, and operating expenses fell 45% to $1.2 million. Cash balance on March 31, 2026 was $245 thousand, including restricted cash. Management highlighted ongoing work with the FDA on infant formula commercialization and parallel efforts to secure a listing on the Canadian Securities Exchange while addressing TSX delisting challenges.
Else Nutrition (OTCQX: BABYF) applauded the Trump Administration's FY2027 budget request, which proposes an approximately $108.5 million increase to FDA Human Foods Program funding versus FY2026 to support infant formula modernization. Else highlighted FDA priority listing for infant formula and an expected 2026 final Protein Efficiency Ratio (PER) guidance as potential catalysts for plant-based, non-soy, non-dairy formula innovation.
Else said these regulatory shifts and initiatives like Operation Stork Speed could expand FDA resources, clinical validation pathways, and pathway clarity for next-generation formulations while the company monitors developments.
Else Nutrition (OTCQX: BABYF) said the FDA has listed Protein Efficiency Ratio (PER) Rat Bioassay Study Guidance as an active topic in its Foods Program on March 10, 2026. Else states this advances scientific expectations for protein quality in novel infant formulas and may reduce regulatory uncertainty for plant‑based formulas.
The company highlights alignment with federal modernization efforts including Operation Stork Speed and says clearer guidance could accelerate U.S. commercialization potential for its plant‑based infant formula.
Else Nutrition (OTC: BABYF) announced it has surpassed one million cans sold across its toddler and kids powder product lines as of Jan 29, 2026. The milestone is presented as evidence of accelerating consumer demand for clean, non-dairy, non-soy, gluten-free childhood nutrition.
The company highlights thousands of parent testimonials reporting improvements in GI sensitivities, CMPA, eczema and feeding issues, and says it is advancing U.S. regulatory efforts for plant-based infant formula under Operation Stock Speed.
Else Nutrition Holdings (OTCQX: BABYF, TSX: BABY) reported results from its annual general meeting held December 29, 2025. Shareholders representing 6,473,877 shares (17.30%) of issued and outstanding shares attended.
Shareholders approved setting the board size at five directors and re-elected all management nominees with individual "for" votes ranging from 97.56% to 99.17%. The meeting also approved re-appointing Kost Forer Gabbay & Kassierer (Ernst & Young member firm) as auditor, the issuance of common shares to Lind Global Fund II, LP and Lind Global Fund III, LP under existing convertible security agreements, and the continuation of the company’s stock option plan. Voting details are available on the company’s SEDAR+ profile.
Else Nutrition (OTC: BABYF / TSX: BABY) appointed Natie Zilberberg as Chief Financial Officer and Corporate Secretary effective January 5, 2026, replacing Shay Shamir. Mr. Zilberberg has 10+ years of finance experience at VC-backed firms across fintech, agrotech, and renewable energy and previously served as CFO of Tomgrow and Financial Controller at Salaryo. His background includes leading strategic financial planning, securing credit facilities, shortening reporting cycles, supporting equity and debt raises, and executing a $30 million acquisition.
Else Nutrition (OTC: BABYF) reported that 2025 was a transformational year, including company-wide cost and headcount reductions, supply-chain and manufacturing efficiency improvements, and focused marketing investments to prioritize toddler and baby cereal categories. The company said temporary production funding shortfalls in 2025 caused supply constraints and revenue losses, and expects more stable inventory and revenue growth in 2026 with improved funding and lower operating costs. In November 2025, a U.S. congressional directive and FDA funding package was signed to streamline approval pathways for non-dairy, non-soy plant-based infant formulas, which Else says improves its regulatory outlook. Else expects to pursue manufacturing efficiencies and aims for cash-flow breakeven between late 2026 and early 2027.
Else Nutrition (TSX: BABY / OTC: BABYF) announced that its 2025 annual general meeting of shareholders will be held on December 29, 2025. The company said a notice, management information circular, and form of proxy were mailed to shareholders of record as of November 10, 2025.
The company also confirmed it received TSX approval to extend the date to hold the annual general meeting.
Else Nutrition (OTC: BABYF) on Nov 18, 2025 said the Fiscal Year 2026 U.S. federal budget signed by President Trump includes Congressional report language (H. Rept. 119-172) that directs the FDA to streamline regulatory pathways and issue formal guidance for plant-based, non-soy, non-dairy infant formulas.
The company says the provision—linked to Operation Stork Speed—was advanced through its government affairs efforts and that FDA guidance work may begin as federal employees return following the government shutdown. Else states it is positioned to accelerate regulator engagement and pursue U.S. infant-formula market access once guidance is implemented.
Else Nutrition (OTC:BABYF) reported Q3 2025 results for the quarter ended Sept 30, 2025, showing a pronounced operational turnaround. Gross profit margin expanded to 34% (versus -9% in Q3 2024). Operating expenses fell 68% to $1.15M, and operating loss narrowed to $0.58M from $3.72M a year earlier. revenue was $1.66M (down from $1.79M) amid temporary out-of-stock issues. Cash at quarter-end was $91K and trade payables declined 46% to $1.53M. Management hosted a conference call Nov 17, 2025 and cited ongoing regulatory, clinical and partnership work to support future commercialization.